On the Frontlines of ATTR-CM
Welcome to On the Frontlines of ATTR-CM, a series that delivers timely, practice-relevant insights from leading experts who are shaping the field. So whether you’re sharpening your diagnostic skills or staying ahead of therapeutic advances, tune in to gain knowledge that can help transform patient outcomes.
Early Detection of ATTR-CM: Clinical Clues and Imaging Approaches
On the Frontlines of ATTR-CMEarly Detection of ATTR-CM: Clinical Clues and Imaging Approaches
Shelina Ramnarine, PhD
Valmiki Maharaj, MD
Recognizing and Managing Swelling in ATTR-CM
On the Frontlines of ATTR-CMRecognizing and Managing Swelling in ATTR-CM
Steve Jackson, PharmD
Kevin S. Shah, MD
Understanding Real-World Testing Patterns in ATTR-CM
On the Frontlines of ATTR-CMUnderstanding Real-World Testing Patterns in ATTR-CM
Steve Jackson, PharmD
Ronald Witteles, MD
Recognizing ATTR-CM in High-Risk Populations
On the Frontlines of ATTR-CMRecognizing ATTR-CM in High-Risk Populations
Steve Jackson, PharmD
Frederick Ruberg, MD
Redefining ATTR-CM Care in the Age of Targeted Therapy
On the Frontlines of ATTR-CMRedefining ATTR-CM Care in the Age of Targeted Therapy
Steve Jackson, PharmD
David Rind, MD, MSc
Tracking Disease Progression in ATTR-CM
On the Frontlines of ATTR-CMTracking Disease Progression in ATTR-CM
Ryan Quigley
Joban Vaishnav, MD
Understanding Vutrisiran’s Cardiac Effects in HELIOS-B
On the Frontlines of ATTR-CMUnderstanding Vutrisiran’s Cardiac Effects in HELIOS-B
Steve Jackson, PharmD
Karola Jering, MD
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
On the Frontlines of ATTR-CMRNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
Shelina Ramnarine, PhD
Chadi Alraies, MD, MPH, FACC
Can AI Transform How We Diagnose ATTR-CM?
On the Frontlines of ATTR-CMCan AI Transform How We Diagnose ATTR-CM?
Ryan Quigley
Frederick Ruberg, MD
ATTRibute-CM Findings on Acoramidis and Cumulative CV Events
On the Frontlines of ATTR-CMATTRibute-CM Findings on Acoramidis and Cumulative CV Events
Ryan Quigley
Ahmad Masri, MD, MS
ATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
On the Frontlines of ATTR-CMATTRibute-CM Trial Updates: Long-Term Outcomes With Acoramidis
Ryan Quigley
Kevin Alexander, MD
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
On the Frontlines of ATTR-CMPatient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
Ryan Quigley
Quan Bui, MD
Exploring Patient Perspectives on Genetic Testing for ATTR-CM
On the Frontlines of ATTR-CMExploring Patient Perspectives on Genetic Testing for ATTR-CM
Shelina Ramnarine, PhD
Quan Bui, MD
Managing Genotype-Positive Patients in Hereditary ATTR-CM
On the Frontlines of ATTR-CMManaging Genotype-Positive Patients in Hereditary ATTR-CM
Shelina Ramnarine, PhD
Naveen L. Pereira, MD
The Cost of Progress: Examining Barriers to ATTR-CM Care
On the Frontlines of ATTR-CMThe Cost of Progress: Examining Barriers to ATTR-CM Care
Charles Turck, PharmD, BCPS, BCCCP
Michelle Kittleson, MD, PhD
- advertisement
